SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiovascular risk http://ow.ly/p6Is300ffoc.</p
peer reviewedRationale: The efficacy of intensified combination therapy with inhaled corticosteroids...
Background: Indacaterol is an inhaled, once-daily, ultra-long-acting beta(2)-agonist for the treatme...
The British Lung Foundation and Newham National Health Service Trust Research and Development funded...
SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiov...
SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiov...
The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronou...
The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that c...
Purpose: COPD exacerbations are associated with worsening clinical outcomes and increased healthcare...
COPD is one of the major public health problems in people aged 40 years or above. It is currently th...
Introduction: Chronic obstructive pulmonary disease (COPD) therapy includes a multi-dimensional appr...
Patients with Chronic Obstructive Pulmonary Disease (COPD) have a lung disorder that limits daily ac...
RATIONALE: Targeted Lung Denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for CO...
Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a large, multicentre, ...
peer reviewedRationale: The efficacy of intensified combination therapy with inhaled corticosteroids...
Background: Indacaterol is an inhaled, once-daily, ultra-long-acting beta(2)-agonist for the treatme...
The British Lung Foundation and Newham National Health Service Trust Research and Development funded...
SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiov...
SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiov...
The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronou...
The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that c...
Purpose: COPD exacerbations are associated with worsening clinical outcomes and increased healthcare...
COPD is one of the major public health problems in people aged 40 years or above. It is currently th...
Introduction: Chronic obstructive pulmonary disease (COPD) therapy includes a multi-dimensional appr...
Patients with Chronic Obstructive Pulmonary Disease (COPD) have a lung disorder that limits daily ac...
RATIONALE: Targeted Lung Denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for CO...
Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a large, multicentre, ...
peer reviewedRationale: The efficacy of intensified combination therapy with inhaled corticosteroids...
Background: Indacaterol is an inhaled, once-daily, ultra-long-acting beta(2)-agonist for the treatme...
The British Lung Foundation and Newham National Health Service Trust Research and Development funded...
DOI
Add to ORKG